Stratified Risk Score Developed for Burkitt's Lymphoma

Brown University researchers have developed a stratified risk score for patient prognosis in the treatment response of patients with Burkitt’s lymphoma.

The team of researchers was lead by Dr. Jorge Castillo, an assistant professor of medicine at the Warren Alpert Medical School of Brown University and a hematology/oncology specialist at Rhode Island Hospital.

The study

Castillo and colleagues looked at the records of 2,284 Burkitt's patients during a period of 11 years.

Using factors including survival rates, age, race, cancer location and cancer stage they created a risk score. Patients with the lowest score have a 7 of 10 chance of survival with treatment, while patients with a 10 have less than 3 in 10 chance of survival.

The findings

Investigators determined that age plays a huge role in survival; notably, patients older than 80 have a five times higher risk of dying from the disease than patients aged 20-39 years. Furthermore, advanced stage Burkitt's (Stage IV) patients are almost two and a half times at greater risk of of dying compared to those in early stages (Stage I).

Looking at the positive

Some good news included the fact that survival rates have been boosted substantially over time. For the younger patients, the rate of overall survival in 1998 was 34.7 percent compared to 62.1 percent today for this same patient population.

Oncologists can use this score to help them make treatment decisions as well as inform patients on their choices.

Burkitt's lymphoma is a rare subtype of non-Hodgkin's lymphoma. It is of B-cell origin and represents fewer than 2 percent of all lymphoid cancers.

Source: doctortipster

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...